Screening of specific antigens for SARS clinical diagnosis using a protein microarray
Identifieur interne : 004965 ( Main/Exploration ); précédent : 004964; suivant : 004966Screening of specific antigens for SARS clinical diagnosis using a protein microarray
Auteurs : Dan-Dan Lu [République populaire de Chine] ; Su-Hong Chen [République populaire de Chine] ; Shi-Meng Zhang [République populaire de Chine] ; Min-Li Zhang [République populaire de Chine] ; Wei Zhang [République populaire de Chine] ; Xiao-Chen Bo [République populaire de Chine] ; Sheng-Qi Wang [République populaire de Chine]Source :
- Analyst [ 0003-2654 ] ; 2005.
Descripteurs français
- KwdFr :
- Analyse par réseau de protéines, Anticorps antiviraux (analyse), Antigènes viraux (isolement et purification), Bioréacteurs, Escherichia coli, Humains, Immunoglobuline G (analyse), Protéines de fusion recombinantes (analyse), Protéines et peptides de signalisation intracellulaire (génétique), Protéines membranaires, Sensibilité et spécificité, Spectrométrie de masse MALDI, Syndrome respiratoire aigu sévère (diagnostic), Syndrome respiratoire aigu sévère (virologie), Test ELISA (), Transporteurs d'anions organiques (génétique), Virus du SRAS (immunologie), Électrophorèse sur gel de polyacrylamide, Études cas-témoins.
- MESH :
- analyse : Anticorps antiviraux, Immunoglobuline G, Protéines de fusion recombinantes.
- diagnostic : Syndrome respiratoire aigu sévère.
- génétique : Protéines et peptides de signalisation intracellulaire, Transporteurs d'anions organiques.
- immunologie : Virus du SRAS.
- isolement et purification : Antigènes viraux.
- virologie : Syndrome respiratoire aigu sévère.
- Analyse par réseau de protéines, Bioréacteurs, Escherichia coli, Humains, Protéines membranaires, Sensibilité et spécificité, Spectrométrie de masse MALDI, Test ELISA, Électrophorèse sur gel de polyacrylamide, Études cas-témoins.
English descriptors
- KwdEn :
- Antibodies, Viral (analysis), Antigens, Viral (isolation & purification), Bioreactors, Case-Control Studies, Electrophoresis, Polyacrylamide Gel, Enzyme-Linked Immunosorbent Assay (methods), Escherichia coli, Humans, Immunoglobulin G (analysis), Intracellular Signaling Peptides and Proteins (genetics), Membrane Proteins, Organic Anion Transporters (genetics), Protein Array Analysis, Recombinant Fusion Proteins (analysis), SARS Virus (immunology), Sensitivity and Specificity, Severe Acute Respiratory Syndrome (diagnosis), Severe Acute Respiratory Syndrome (virology), Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization.
- MESH :
- chemical , analysis : Antibodies, Viral, Immunoglobulin G, Recombinant Fusion Proteins.
- chemical , genetics : Intracellular Signaling Peptides and Proteins, Organic Anion Transporters.
- chemical , isolation & purification : Antigens, Viral.
- diagnosis : Severe Acute Respiratory Syndrome.
- immunology : SARS Virus.
- methods : Enzyme-Linked Immunosorbent Assay.
- virology : Severe Acute Respiratory Syndrome.
- Teeft :
- Affinity column, Amersham pharmacia, Amino acids, Antibody screening, Antibody testing, Antigen screening platform, Antigenic, Antisense primers, Assay, Beijing, Beijing hospital, Bioreactors, Calibration curve, Calibration curves, Case-Control Studies, Cell lysates, Clinical assessment, Clinical diagnosis, Clinical patient sera, Clinical trials, Coli, Coli dh5a, Convalescent patients, Coronavirus, Cutoff value, Detection limits, Detection wavelength, Different reactivities, Electrophoresis, Polyacrylamide Gel, Elisa, Elisa assay, Epidemiologic investigations, Escherichia coli, Experimental conditions, Expression plasmids, Fluorescence intensity, Fragment, Fusion protein, Fusion proteins, Gaattc, Gene fragments, Gene nucleotide sequence, Gene sequence, Ggatcc, Glass slides, Healthy individuals, High degree, Host cells, Human sera, Humans, Inpatient, Internal calibration curves, Lysates, Membrane Proteins, Microarray, Microarray assay, Microarrays, Molecular protein standards, Molecular weight, Negative control, Negative control sera, Negative sera, Novel coronavirus, Nucleocapsid proteins, Nucleotide, Nucleotide sequences, Oligonucleotide primers, Plasmid, Positive rates, Positive reactivity, Positive sera, Primer, Probable sars patients, Protein, Protein Array Analysis, Protein fragment screening microarray, Protein fragment screening microarrays, Protein fragments, Protein microarray, Protein microarray assay, Protein microarrays, Protein microarrays protein microarrays, Recombinant, Recombinant fusion protein, Recombinant proteins, Respiratory syndrome, Restriction sites, Royal society, Sars, Sars diagnosis, Sars disease, Sars infection, Sars inpatients, Sars outbreak, Sars patients, Sars sera, Scan images, Schematic representation, Screening, Screening microarrays, Sensitivity and Specificity, Sensitivity control sample, Serum samples, Sonication buffer, Specific antibodies, Specific antigens, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Structural proteins, Structure protein screening microarrays, Traditional chinese, Various structure proteins, Vector protein, Western medicine.
Abstract
In this study several SARS-CoV structural proteins and fragments were expressed in E. coli as GST or TRX fusion proteins. They were fabricated on a microarray and tested with sera from SARS patients. Antigenic screening indicated that recombinant GST-N2 fusion protein, the carboxy-terminus 213aa–423aa of N protein, was strongest positive and weakest non-specific compared with others. An indirect antibody ELISA method was developed and clinical positive and negative sera for their antibodies against GST-N2 fusion protein were assayed. 311 out of the 442 sera from clinical SARS inpatients, as well as 229 out of 302 sera from convalescent patients gave positive reactivities; positive rates were 70.4% and 75.8% respectively. Sera from a total of 2726 non-SARS patients and healthy individuals were tested and the false positive rate was only 0.07%. When the sensitivity control sample was diluted 1 ∶ 64, it yielded OD values above the cutoff value. Reported data showed that this was a relatively high degree of sensitivity and specificity for SARS-CoV antibody testing. The data indicate that GST-N2 fusion protein, which was screened by protein microarray, may be a valuable diagnostic antigen for the development of serological assays for SARS. In addition, protein microarray assay presents a higher positive rate and sensitivity (86.1% and 1 ∶ 200) compared with the traditional ELISA screening method, and could provide a rapid, parallel and high-throughput antigen screening platform.
Url:
DOI: 10.1039/b415888a
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000001
- to stream Istex, to step Curation: 000001
- to stream Istex, to step Checkpoint: 001826
- to stream PubMed, to step Corpus: 002837
- to stream PubMed, to step Curation: 002837
- to stream PubMed, to step Checkpoint: 002503
- to stream Ncbi, to step Merge: 000E44
- to stream Ncbi, to step Curation: 000E44
- to stream Ncbi, to step Checkpoint: 000E44
- to stream Main, to step Merge: 004C93
- to stream Main, to step Curation: 004965
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Screening of specific antigens for SARS clinical diagnosis using a protein microarray</title>
<author wicri:is="90%"><name sortKey="Lu, Dan Dan" sort="Lu, Dan Dan" uniqKey="Lu D" first="Dan-Dan" last="Lu">Dan-Dan Lu</name>
</author>
<author wicri:is="90%"><name sortKey="Chen, Su Hong" sort="Chen, Su Hong" uniqKey="Chen S" first="Su-Hong" last="Chen">Su-Hong Chen</name>
</author>
<author wicri:is="90%"><name sortKey="Zhang, Shi Meng" sort="Zhang, Shi Meng" uniqKey="Zhang S" first="Shi-Meng" last="Zhang">Shi-Meng Zhang</name>
</author>
<author wicri:is="90%"><name sortKey="Zhang, Min Li" sort="Zhang, Min Li" uniqKey="Zhang M" first="Min-Li" last="Zhang">Min-Li Zhang</name>
</author>
<author wicri:is="90%"><name sortKey="Zhang, Wei" sort="Zhang, Wei" uniqKey="Zhang W" first="Wei" last="Zhang">Wei Zhang</name>
</author>
<author wicri:is="90%"><name sortKey="Bo, Xiao Chen" sort="Bo, Xiao Chen" uniqKey="Bo X" first="Xiao-Chen" last="Bo">Xiao-Chen Bo</name>
</author>
<author wicri:is="90%"><name sortKey="Wang, Sheng Qi" sort="Wang, Sheng Qi" uniqKey="Wang S" first="Sheng-Qi" last="Wang">Sheng-Qi Wang</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:ED6A1E05919B52ABD2FC81D99BBBC2623094027C</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1039/b415888a</idno>
<idno type="url">https://api.istex.fr/ark:/67375/QHD-7B8CRX67-C/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000001</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000001</idno>
<idno type="wicri:Area/Istex/Curation">000001</idno>
<idno type="wicri:Area/Istex/Checkpoint">001826</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001826</idno>
<idno type="wicri:doubleKey">0003-2654:2005:Lu D:screening:of:specific</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15776156</idno>
<idno type="wicri:Area/PubMed/Corpus">002837</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002837</idno>
<idno type="wicri:Area/PubMed/Curation">002837</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002837</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002503</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002503</idno>
<idno type="wicri:Area/Ncbi/Merge">000E44</idno>
<idno type="wicri:Area/Ncbi/Curation">000E44</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000E44</idno>
<idno type="wicri:doubleKey">0003-2654:2005:Lu D:screening:of:specific</idno>
<idno type="wicri:Area/Main/Merge">004C93</idno>
<idno type="wicri:Area/Main/Curation">004965</idno>
<idno type="wicri:Area/Main/Exploration">004965</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a">Screening of specific antigens for SARS clinical diagnosis using a protein microarray</title>
<author wicri:is="90%"><name sortKey="Lu, Dan Dan" sort="Lu, Dan Dan" uniqKey="Lu D" first="Dan-Dan" last="Lu">Dan-Dan Lu</name>
<affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Beijing Institute of Radiation Medicine, 100850, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">République populaire de Chine</country>
</affiliation>
</author>
<author wicri:is="90%"><name sortKey="Chen, Su Hong" sort="Chen, Su Hong" uniqKey="Chen S" first="Su-Hong" last="Chen">Su-Hong Chen</name>
<affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Beijing Institute of Radiation Medicine, 100850, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">République populaire de Chine</country>
</affiliation>
</author>
<author wicri:is="90%"><name sortKey="Zhang, Shi Meng" sort="Zhang, Shi Meng" uniqKey="Zhang S" first="Shi-Meng" last="Zhang">Shi-Meng Zhang</name>
<affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Beijing Institute of Radiation Medicine, 100850, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">République populaire de Chine</country>
</affiliation>
</author>
<author wicri:is="90%"><name sortKey="Zhang, Min Li" sort="Zhang, Min Li" uniqKey="Zhang M" first="Min-Li" last="Zhang">Min-Li Zhang</name>
<affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Beijing Institute of Radiation Medicine, 100850, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">République populaire de Chine</country>
</affiliation>
</author>
<author wicri:is="90%"><name sortKey="Zhang, Wei" sort="Zhang, Wei" uniqKey="Zhang W" first="Wei" last="Zhang">Wei Zhang</name>
<affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Beijing Institute of Radiation Medicine, 100850, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">République populaire de Chine</country>
</affiliation>
</author>
<author wicri:is="90%"><name sortKey="Bo, Xiao Chen" sort="Bo, Xiao Chen" uniqKey="Bo X" first="Xiao-Chen" last="Bo">Xiao-Chen Bo</name>
<affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Beijing Institute of Radiation Medicine, 100850, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">République populaire de Chine</country>
</affiliation>
</author>
<author wicri:is="90%"><name sortKey="Wang, Sheng Qi" sort="Wang, Sheng Qi" uniqKey="Wang S" first="Sheng-Qi" last="Wang">Sheng-Qi Wang</name>
<affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Beijing Institute of Radiation Medicine, 100850, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">République populaire de Chine</country>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Analyst</title>
<title level="j" type="abbrev">Analyst</title>
<idno type="ISSN">0003-2654</idno>
<idno type="eISSN">1364-5528</idno>
<imprint><publisher>The Royal Society of Chemistry.</publisher>
<date type="published" when="2005">2005</date>
<biblScope unit="volume">130</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="474">474</biblScope>
<biblScope unit="page" to="482">482</biblScope>
</imprint>
<idno type="ISSN">0003-2654</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0003-2654</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Viral (analysis)</term>
<term>Antigens, Viral (isolation & purification)</term>
<term>Bioreactors</term>
<term>Case-Control Studies</term>
<term>Electrophoresis, Polyacrylamide Gel</term>
<term>Enzyme-Linked Immunosorbent Assay (methods)</term>
<term>Escherichia coli</term>
<term>Humans</term>
<term>Immunoglobulin G (analysis)</term>
<term>Intracellular Signaling Peptides and Proteins (genetics)</term>
<term>Membrane Proteins</term>
<term>Organic Anion Transporters (genetics)</term>
<term>Protein Array Analysis</term>
<term>Recombinant Fusion Proteins (analysis)</term>
<term>SARS Virus (immunology)</term>
<term>Sensitivity and Specificity</term>
<term>Severe Acute Respiratory Syndrome (diagnosis)</term>
<term>Severe Acute Respiratory Syndrome (virology)</term>
<term>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Analyse par réseau de protéines</term>
<term>Anticorps antiviraux (analyse)</term>
<term>Antigènes viraux (isolement et purification)</term>
<term>Bioréacteurs</term>
<term>Escherichia coli</term>
<term>Humains</term>
<term>Immunoglobuline G (analyse)</term>
<term>Protéines de fusion recombinantes (analyse)</term>
<term>Protéines et peptides de signalisation intracellulaire (génétique)</term>
<term>Protéines membranaires</term>
<term>Sensibilité et spécificité</term>
<term>Spectrométrie de masse MALDI</term>
<term>Syndrome respiratoire aigu sévère (diagnostic)</term>
<term>Syndrome respiratoire aigu sévère (virologie)</term>
<term>Test ELISA ()</term>
<term>Transporteurs d'anions organiques (génétique)</term>
<term>Virus du SRAS (immunologie)</term>
<term>Électrophorèse sur gel de polyacrylamide</term>
<term>Études cas-témoins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Antibodies, Viral</term>
<term>Immunoglobulin G</term>
<term>Recombinant Fusion Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Intracellular Signaling Peptides and Proteins</term>
<term>Organic Anion Transporters</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>Antigens, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Immunoglobuline G</term>
<term>Protéines de fusion recombinantes</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Protéines et peptides de signalisation intracellulaire</term>
<term>Transporteurs d'anions organiques</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Antigènes viraux</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Enzyme-Linked Immunosorbent Assay</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Affinity column</term>
<term>Amersham pharmacia</term>
<term>Amino acids</term>
<term>Antibody screening</term>
<term>Antibody testing</term>
<term>Antigen screening platform</term>
<term>Antigenic</term>
<term>Antisense primers</term>
<term>Assay</term>
<term>Beijing</term>
<term>Beijing hospital</term>
<term>Bioreactors</term>
<term>Calibration curve</term>
<term>Calibration curves</term>
<term>Case-Control Studies</term>
<term>Cell lysates</term>
<term>Clinical assessment</term>
<term>Clinical diagnosis</term>
<term>Clinical patient sera</term>
<term>Clinical trials</term>
<term>Coli</term>
<term>Coli dh5a</term>
<term>Convalescent patients</term>
<term>Coronavirus</term>
<term>Cutoff value</term>
<term>Detection limits</term>
<term>Detection wavelength</term>
<term>Different reactivities</term>
<term>Electrophoresis, Polyacrylamide Gel</term>
<term>Elisa</term>
<term>Elisa assay</term>
<term>Epidemiologic investigations</term>
<term>Escherichia coli</term>
<term>Experimental conditions</term>
<term>Expression plasmids</term>
<term>Fluorescence intensity</term>
<term>Fragment</term>
<term>Fusion protein</term>
<term>Fusion proteins</term>
<term>Gaattc</term>
<term>Gene fragments</term>
<term>Gene nucleotide sequence</term>
<term>Gene sequence</term>
<term>Ggatcc</term>
<term>Glass slides</term>
<term>Healthy individuals</term>
<term>High degree</term>
<term>Host cells</term>
<term>Human sera</term>
<term>Humans</term>
<term>Inpatient</term>
<term>Internal calibration curves</term>
<term>Lysates</term>
<term>Membrane Proteins</term>
<term>Microarray</term>
<term>Microarray assay</term>
<term>Microarrays</term>
<term>Molecular protein standards</term>
<term>Molecular weight</term>
<term>Negative control</term>
<term>Negative control sera</term>
<term>Negative sera</term>
<term>Novel coronavirus</term>
<term>Nucleocapsid proteins</term>
<term>Nucleotide</term>
<term>Nucleotide sequences</term>
<term>Oligonucleotide primers</term>
<term>Plasmid</term>
<term>Positive rates</term>
<term>Positive reactivity</term>
<term>Positive sera</term>
<term>Primer</term>
<term>Probable sars patients</term>
<term>Protein</term>
<term>Protein Array Analysis</term>
<term>Protein fragment screening microarray</term>
<term>Protein fragment screening microarrays</term>
<term>Protein fragments</term>
<term>Protein microarray</term>
<term>Protein microarray assay</term>
<term>Protein microarrays</term>
<term>Protein microarrays protein microarrays</term>
<term>Recombinant</term>
<term>Recombinant fusion protein</term>
<term>Recombinant proteins</term>
<term>Respiratory syndrome</term>
<term>Restriction sites</term>
<term>Royal society</term>
<term>Sars</term>
<term>Sars diagnosis</term>
<term>Sars disease</term>
<term>Sars infection</term>
<term>Sars inpatients</term>
<term>Sars outbreak</term>
<term>Sars patients</term>
<term>Sars sera</term>
<term>Scan images</term>
<term>Schematic representation</term>
<term>Screening</term>
<term>Screening microarrays</term>
<term>Sensitivity and Specificity</term>
<term>Sensitivity control sample</term>
<term>Serum samples</term>
<term>Sonication buffer</term>
<term>Specific antibodies</term>
<term>Specific antigens</term>
<term>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</term>
<term>Structural proteins</term>
<term>Structure protein screening microarrays</term>
<term>Traditional chinese</term>
<term>Various structure proteins</term>
<term>Vector protein</term>
<term>Western medicine</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Analyse par réseau de protéines</term>
<term>Bioréacteurs</term>
<term>Escherichia coli</term>
<term>Humains</term>
<term>Protéines membranaires</term>
<term>Sensibilité et spécificité</term>
<term>Spectrométrie de masse MALDI</term>
<term>Test ELISA</term>
<term>Électrophorèse sur gel de polyacrylamide</term>
<term>Études cas-témoins</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract">In this study several SARS-CoV structural proteins and fragments were expressed in E. coli as GST or TRX fusion proteins. They were fabricated on a microarray and tested with sera from SARS patients. Antigenic screening indicated that recombinant GST-N2 fusion protein, the carboxy-terminus 213aa–423aa of N protein, was strongest positive and weakest non-specific compared with others. An indirect antibody ELISA method was developed and clinical positive and negative sera for their antibodies against GST-N2 fusion protein were assayed. 311 out of the 442 sera from clinical SARS inpatients, as well as 229 out of 302 sera from convalescent patients gave positive reactivities; positive rates were 70.4% and 75.8% respectively. Sera from a total of 2726 non-SARS patients and healthy individuals were tested and the false positive rate was only 0.07%. When the sensitivity control sample was diluted 1 ∶ 64, it yielded OD values above the cutoff value. Reported data showed that this was a relatively high degree of sensitivity and specificity for SARS-CoV antibody testing. The data indicate that GST-N2 fusion protein, which was screened by protein microarray, may be a valuable diagnostic antigen for the development of serological assays for SARS. In addition, protein microarray assay presents a higher positive rate and sensitivity (86.1% and 1 ∶ 200) compared with the traditional ELISA screening method, and could provide a rapid, parallel and high-throughput antigen screening platform.</div>
</front>
</TEI>
<affiliations><list><country><li>République populaire de Chine</li>
</country>
<settlement><li>Pékin</li>
</settlement>
</list>
<tree><country name="République populaire de Chine"><noRegion><name sortKey="Lu, Dan Dan" sort="Lu, Dan Dan" uniqKey="Lu D" first="Dan-Dan" last="Lu">Dan-Dan Lu</name>
</noRegion>
<name sortKey="Bo, Xiao Chen" sort="Bo, Xiao Chen" uniqKey="Bo X" first="Xiao-Chen" last="Bo">Xiao-Chen Bo</name>
<name sortKey="Bo, Xiao Chen" sort="Bo, Xiao Chen" uniqKey="Bo X" first="Xiao-Chen" last="Bo">Xiao-Chen Bo</name>
<name sortKey="Chen, Su Hong" sort="Chen, Su Hong" uniqKey="Chen S" first="Su-Hong" last="Chen">Su-Hong Chen</name>
<name sortKey="Chen, Su Hong" sort="Chen, Su Hong" uniqKey="Chen S" first="Su-Hong" last="Chen">Su-Hong Chen</name>
<name sortKey="Lu, Dan Dan" sort="Lu, Dan Dan" uniqKey="Lu D" first="Dan-Dan" last="Lu">Dan-Dan Lu</name>
<name sortKey="Wang, Sheng Qi" sort="Wang, Sheng Qi" uniqKey="Wang S" first="Sheng-Qi" last="Wang">Sheng-Qi Wang</name>
<name sortKey="Wang, Sheng Qi" sort="Wang, Sheng Qi" uniqKey="Wang S" first="Sheng-Qi" last="Wang">Sheng-Qi Wang</name>
<name sortKey="Zhang, Min Li" sort="Zhang, Min Li" uniqKey="Zhang M" first="Min-Li" last="Zhang">Min-Li Zhang</name>
<name sortKey="Zhang, Min Li" sort="Zhang, Min Li" uniqKey="Zhang M" first="Min-Li" last="Zhang">Min-Li Zhang</name>
<name sortKey="Zhang, Shi Meng" sort="Zhang, Shi Meng" uniqKey="Zhang S" first="Shi-Meng" last="Zhang">Shi-Meng Zhang</name>
<name sortKey="Zhang, Shi Meng" sort="Zhang, Shi Meng" uniqKey="Zhang S" first="Shi-Meng" last="Zhang">Shi-Meng Zhang</name>
<name sortKey="Zhang, Wei" sort="Zhang, Wei" uniqKey="Zhang W" first="Wei" last="Zhang">Wei Zhang</name>
<name sortKey="Zhang, Wei" sort="Zhang, Wei" uniqKey="Zhang W" first="Wei" last="Zhang">Wei Zhang</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004965 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004965 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:ED6A1E05919B52ABD2FC81D99BBBC2623094027C |texte= Screening of specific antigens for SARS clinical diagnosis using a protein microarray }}
This area was generated with Dilib version V0.6.33. |